NanoViricides progresses antiviral portfolio as measles and MPox...
NanoViricides (NYSE-A:NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid rising concern over vaccine failure and the lack of effective …